Literature DB >> 26017379

[Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI].

A Radbruch1, E Hattingen.   

Abstract

Due to the introduction of advanced functional and spectroscopic magnetic resonance (MR) sequences, MR imaging has gained significant importance in neuro-oncology. In contrast to recent years when neuro-oncological imaging was mostly limited to contrast-enhanced T1-weighted images, advanced MR methods provide direct visualization and assessment of tumor pathophysiology. This article summarizes the most relevant MR methods for neuro-oncological imaging and highlights the pathophysiological background as well as potential clinical applications. Ultimately, this article gives a glimpse into the future and introduces potential applications of ultra-high field MRI.

Entities:  

Mesh:

Year:  2015        PMID: 26017379     DOI: 10.1007/s00115-015-4313-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  56 in total

1.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

Review 2.  Pros and cons of current brain tumor imaging.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Martin J van den Bent; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.

Authors:  E E Graves; S J Nelson; D B Vigneron; L Verhey; M McDermott; D Larson; S Chang; M D Prados; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

4.  Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors.

Authors:  Taiichi Saito; Fumiyuki Yamasaki; Yoshinori Kajiwara; Nobukazu Abe; Yuji Akiyama; Takako Kakuda; Yukio Takeshima; Kazuhiko Sugiyama; Yoshikazu Okada; Kaoru Kurisu
Journal:  Eur J Radiol       Date:  2011-05-04       Impact factor: 3.528

5.  Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.

Authors:  W B Pope; A Lai; R Mehta; H J Kim; J Qiao; J R Young; X Xue; J Goldin; M S Brown; P L Nghiemphu; A Tran; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

6.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

7.  IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Authors:  Morteza Esmaeili; Bob C Hamans; Anna C Navis; Remco van Horssen; Tone F Bathen; Ingrid S Gribbestad; William P Leenders; Arend Heerschap
Journal:  Cancer Res       Date:  2014-07-08       Impact factor: 12.701

8.  Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study.

Authors:  H S Kim; G-H Jahng; C W Ryu; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2009-05-20       Impact factor: 3.825

9.  Nuclear overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 Tesla in glioblastoma patients.

Authors:  Daniel Paech; Moritz Zaiss; Jan-Eric Meissner; Johannes Windschuh; Benedikt Wiestler; Peter Bachert; Jan Oliver Neumann; Philipp Kickingereder; Heinz-Peter Schlemmer; Wolfgang Wick; Armin Michael Nagel; Sabine Heiland; Mark Edward Ladd; Martin Bendszus; Alexander Radbruch
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

10.  Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.

Authors:  Elke Hattingen; Oliver Bähr; Johannes Rieger; Stella Blasel; Joachim Steinbach; Ulrich Pilatus
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.